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Abstract
Background: Multikinase inhibitors (MKIs) sunitinib and sorafenib have become a standard of care for metastatic
renal cell carcinoma (mRCC). This study assessed safety and treatment patterns for these agents in a real-world
clinical practice setting in Italy.
Methods: A retrospective medical record review was performed at a tertiary oncology center in Italy. The study
included MKI-naïve non-trial patients ≥18 years old, with a histological diagnosis of mRCC, and who received
sunitinib or sorafenib as first MKI during 9/2005-7/2008. Data were collected on adverse events (AEs), treatment
modifications (discontinuations, interruptions, dose changes), and reasons for these modifications.
Results: 145 patients were included; 85 received sunitinib and 60 received sorafenib as first-line MKI. Median
treatment duration was 6.6 (sunitinib) and 5.8 (sorafenib) months. 97.6% and 70.0% of patients receiving sunitinib
and sorafenib, respectively, experienced ≥1 AE; 27.1% and 31.7% had ≥1 grade 3/4 AE. The most common any
grade AE for sunitinib was fatigue/asthenia (81.2%), followed by mucositis/stomatitis (58.8%) and decreased taste
sensation (42.4%), while for sorafenib this was fatigue/asthenia (43.3%) followed by hand-foot syndrome (38.3%)
and diarrhea (31.7%). Treatment discontinuation, interruption, and dose reduction due to AEs occurred in 11.8%,
23.5%, and 30.6%, respectively, of patients receiving sunitinib, and 5.0%, 23.3%, and 36.7%, respectively, of patients
receiving sorafenib.
Conclusions: In this retrospective study, most patients experienced ≥1 AE during first-line MKI treatment. AEs were
reported frequently and resulted in treatment modifications in 40% of patients receiving sunitinib and 45% of
patients receiving sorafenib. These results suggest a need for additional effective and more tolerable treatments for
mRCC.
Background
Treatment options for metastatic renal cell carcinoma
(mRCC) have grown to include anti-angiogenic agents,
which inhibit the vascular endothelial growth factor
(VEGF) pathway and disrupt tumor growth. Sunitinib
and sorafenib are oral multikinase inhibitors (MKIs) that
have received approval for treatment of RCC in Europe
and the U.S. and have become a standard of care in
mRCC. Both agents have demonstrated efficacy in
tumor shrinkage and prolonged progression-free survival
(PFS) of patients with advanced or metastatic RCC
within randomized clinical trials [1-4].
Clinical trials showed that sunitinib and sorafenib are
commonly associated with certain adverse events,
including fatigue, diarrhea, hypertension and dermatolo-
gic toxicities (rash and hand-foot skin reaction) [1-4].
Other adverse events reported in clinical trials among
patients treated with sunitinib included nausea, stomati-
tis, vomiting, and mucosal inflammation [1,3]. Patients
treated with sorafenib also reported alopecia, nausea,
and anorexia [2,4].* Correspondence: c.porta@smatteo.pv.it1Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation,
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Clinical trials may not be representative of real-life
clinical practice due to strict and homogeneous patient
selection criteria, as patients in clinical trials generally
have fewer comorbidities than those seen in oncology
practice so that the effect of the active treatment can be
better isolated [5]. Thus, observational studies in patients
treated at clinical settings are needed in addition to clini-
cal trials to further examine the safety profiles of suniti-
nib and sorafenib. Expanded-access trials, which enrolled
primarily patients who were not eligible to participate in
clinical trials due to exclusion criteria, have been con-
ducted to examine the efficacy and safety of sunitinib and
sorafenib. In an expanded-access trial for sunitinib that
enrolled 4,564 patients, the most common treatment-
related all-grade adverse events were diarrhea (44%) and
fatigue (37%), and the most common grade 3/4 adverse
event was fatigue (8%) [6]. Reasons for discontinuation
included lack of efficacy (27%) and adverse events (8%).
In an expanded-access trial for sorafenib that enrolled
2,502 patients [7], the most common drug-related
adverse events were rash (26%) and hand-foot syndrome
(23%), and the most common grade 3/4 adverse event
was hand-foot syndrome (8%). Adverse events resulted in
treatment discontinuation in 20% of patients.
Based on data from everyday clinical practice adverse
events among patients taking sunitinib or sorafenib may
be higher than those observed and reported from clini-
cal trials. For example, thyroid dysfunctions, which have
now been identified as one of the frequent tyrosine
kinase-related adverse events, were not reported as such
in the pivotal clinical trial of sunitinib [1,8]. Further-
more, toxicities associated with both sunitinib and sora-
fenib appeared to be higher in the two global expanded
access programs (EAPs) and in reports from single cen-
ters compared to that in the clinical trials [6,7,9]. The
primary objective of this study was to examine the safety
profiles of sunitinib and sorafenib and the frequency of
treatment modifications, including treatment disconti-
nuation, treatment interruptions and dose changes in a
real-world setting at a tertiary oncology center.
Methods
Study Design and Data Source
In this retrospective, observational study, medical records
of eligible patients treated at IRCCS San Matteo Univer-
sity Hospital, Pavia, Italy, were reviewed. Data extracted
from the medical records included but were not limited
to: date of initial RCC diagnosis, demographic variables,
comorbidities, prior pharmacological or radiological
treatments, metastatic site(s), baseline Eastern Coopera-
tive Oncology Group (ECOG) performance status (PS)
score, drug-related adverse event data, laboratory data,
and radiologic test results. Other treatment-related data
collected included dates of treatment initiation and
discontinuation, initial dosing, dates and reasons of treat-
ment interruptions and treatment changes, dosing modi-
fications and follow-up tumor assessments.
The observation period for each patient extended
from the initiation of the first MKI therapy to the ear-
liest of death, loss to follow up, or end of the study per-
iod. Patients who switched to another MKI during the
observation period continued to be followed in the
study, but their observation periods were analyzed sepa-
rately as first-line and second-line treatment. Data on
patients who received the first MKI therapy between
September 2005 and July 2008 were included. This
study was approved by the San Matteo University Hos-
pital’s Ethics Committee.
Study Population
Patients aged 18 years or older with histologically or
cytologically confirmed mRCC who were MKI-naïve
prior to the first dose of sunitinib or sorafenib were eli-
gible to be included in the study. Patients could have
received prior immunotherapy and/or chemotherapy.
Eligible patients were required to have received at least
one dose of sunitinib and/or sorafenib after January 1,
2005. Patients who were enrolled in a RCC clinical trial
at any time during this study or had previously enrolled
in a RCC clinical trial within 6 months prior to the
initiation of MKI therapy were excluded from the study,
but patients who participated in EAPs were permitted.
Patients who had less than 3 months of follow-up data




Safety outcomes included the numbers and proportions
of patients who experienced specific adverse events, of
any grade and of grade 3 or higher. The study investiga-
tors retrospectively assessed toxic events and assigned
grade levels using the National Cancer Institute’s Com-
mon Terminology Criteria for Adverse Events (CTCAE),
version 3.0, at chart abstraction because grade levels of
adverse events are not regularly recorded in medical
charts in clinical settings [10].
Treatment Patterns
Outcomes of treatment patterns included the numbers
and proportions of patients who had a treatment
discontinuation, interruption, or dose change during
first-line MKI treatment, and those who switched to a
second-line MKI treatment. The type, date, and the
reasons for treatment modification were abstracted from
patient medical charts. A treatment interruption
occurred if therapy was held and then later resumed. If
treatment was stopped and never resumed, the patient
was classified as discontinuing therapy.
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Statistical Analyses
Descriptive statistics were used to describe patient base-
line characteristics, adverse events, and treatment pat-
terns. Means, median, and ranges were used to describe
continuous variables; frequencies and percentages were
reported for categorical variables. Median treatment
duration was assessed using the Kaplan-Meier survival




Table 1 shows the baseline demographic and clinical
characteristics of the study patients. A total of 145
patients were included in this study. Among them, 85
patients received sunitinib and 60 patients received
sorafenib as first-line MKI. All 85 patients receiving
sunitinib initiated treatment at the recommended dose
of 50 mg once daily, 4 weeks on, followed by 2 weeks
off (QD, 4/2). 98.3% of patients receiving sorafenib
initiated treatment at the recommended dose of 400 mg
twice daily.
Most patients in both groups had a baseline ECOG PS
score of 0 (81.2% for sunitinib and 58.3% for sorafenib);
only 1 patient in the sorafenib group had an ECOG PS
score of 2. More than half of all patients had 3 or more
metastatic sites at the baseline. The most prevalent
metastatic sites were lung and lymph nodes (60.0%-
76.7%); 16.5% of patients receiving sunitinib and 16.7%
of patients receiving sorafenib had brain metastases at
baseline. Almost all patients had a history of nephrect-
omy and immunotherapy (Table 1).
Safety
Table 2 presents the frequencies and rates of all-grade
and grade 3/4 adverse events observed in the study
population, as reported in patients’ medical charts.
Among patients receiving sunitinib and sorafenib,
97.6% and 70.0%, respectively, experienced at least one
adverse event. The most common all-grade adverse
event for both MKIs was fatigue or asthenia, observed
in 81.2% of patients receiving sunitinib and 43.3% of
patients receiving sorafenib. In patients receiving suni-
tinib, other frequently reported all-grade adverse
events included mucositis or stomatitis (58.8%) and
decreased taste sensation (42.4%). In patients receiving
sorafenib, hand-foot syndrome was the second most
frequently reported all-grade adverse event (38.3%),
followed by diarrhea (31.7%). Fatigue or asthenia was
also the most common grade 3/4 adverse events for
both agents, reported in 9.4% of patients receiving
sunitinib and 10.0% of patients receiving sorafenib.
Other frequently reported grade 3/4 adverse events
included anorexia and vomiting (5.9% each) and hyper-
tension, nausea, and abdominal pain (3.5% each) in
patients treated with sunitinib, and hypertension
(5.0%), hand-foot syndrome, diarrhea, abdominal pain,
skin rash, and dyspnea (3.3% each) in patients treated
with sorafenib.
Treatment Patterns
Table 3 summarizes the treatment patterns for first-line
MKIs and reasons for treatment modifications. The
median duration of first-line MKI treatment was 6.6
months (95% CI: 5.3, 11.1) for sunitinib and 5.8 months
(95% CI: 4.1, 8.1) for sorafenib.
Among patients receiving sunitinib, 77.6% discontin-
ued treatment, 34.1% had a treatment interruption, and
35.3% had a dose reduction. In patients receiving sorafe-
nib, 85.0% discontinued treatment, 26.7% had a
Table 1 Baseline Characteristics among Patients
Receiving First-Line Multikinase Inhibitor Treatment
Sunitinib Sorafenib
(N = 85) (N = 60)
Initial Dose, N (%) 50 mg QD 85
(100.0)
400 mg BID 59
(98.3)
400 mg QD 1 (1.7)
Age at initiation, years
Median (range) 62.4 (35.1-81.9) 66.0 (37.9-77.7)
Mean (std.) 60.1 (10.4) 63.2 (9.7)
Male, N (%) 74 (87.1) 53 (88.3)
ECOG Performance
Status, N (%)
0 69 (81.2) 35 (58.3)
1 14 (16.5) 13 (21.7)
2 0 (0.0) 1 (1.7)
NA 2 (2.4) 11 (18.3)
Number of metastatic
sites
1 8 (9.4) 9 (15.0)
2 30 (35.3) 9 (15.0)
3 25 (29.4) 21 (35.0)
>3 22 (25.9) 21 (35.0)
Metastatic sites, N (%)
Bone 29 (34.1) 18 (30.0)
Brain 14 (16.5) 10 (16.7)
Liver 18 (21.2) 23 (38.3)
Lung 59 (69.4) 46 (76.7)
Lymph nodes 52 (61.2) 36 (60.0)
Previous therapy, N (%)
Radiotherapy 30 (35.3) 21 (35.0)
Nephrectomy 84 (98.8) 58 (96.7)
Immunotherapy 68 (80.0) 49 (81.7)
Chemotherapy 39 (45.9) 28 (46.7)
NA = not available.
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treatment interruption, and 38.3% had a dose reduction.
Progressive disease was the most frequently reported
reason for treatment discontinuation in both groups
(62.4% for sunitinib and 58.3% for sorafenib), followed
by adverse events (11.8% of patients receiving sunitinib
and 5% of patients receiving sorafenib). For both MKIs,
adverse events were the most frequently reported rea-
sons for treatment interruptions (23.5% for sunitinib
and 23.3% for sorafenib) and dose reductions (30.6% for
sunitinib and 36.7% for sorafenib).
Table 3 also describes the reasons for changes in
treatment from one MKI to another. Among patients
who received sunitinib as first-line MKI, 17.6% switched
to sorafenib as a second-line treatment. Among patients
who received sorafenib as first-line MKI treatment,
35.0% switched to second-line treatment with sunitinib
and 3.3% switched to second-line treatment with
temsirolimus.
Table 4 shows the adverse events reported as reasons
for treatment modifications. Forty percent of patients
receiving sunitinib and 45% of patients receiving sorafe-
nib had at least one treatment modification due to
adverse events. The adverse events most frequently
reported as reasons for treatment discontinuation were
anorexia (4.7%) and fatigue/asthenia (3.5%) in patients
receiving sunitinib and fatigue/asthenia (1.7%), dyspnea
(1.7%), abdominal pain (1.7%), and skin rash (1.7%) in
patients receiving sorafenib. The most common adverse
events reported as reasons for treatment interruption
were fatigue/asthenia (9.4%), vomiting (5.9%), and diar-
rhea (5.9%) in patients receiving sunitinib, and diarrhea
(6.7%), hand-foot syndrome (5.0%), and skin rash (5.0%)
in patients receiving sorafenib. The adverse events most
frequently reported as reasons for dose reductions were
fatigue/asthenia (16.5%) and stomatitis/mucositis (4.7%)
in patients receiving sunitinib, and fatigue/asthenia
(20.0%) and hand-foot syndrome (18.3%) in patients
receiving sorafenib.
Discussion
Few published studies on MKIs have examined the
safety and treatment patterns of these agents outside of
clinical trial or EAP settings. This study examined the
safety profiles of sunitinib and sorafenib and their asso-
ciation with treatment patterns as observed in a real-
world clinical setting in Italy. Due to the small sample
size in each treatment group and the observational nat-
ure of this study, statistical comparisons between groups
are not likely to be meaningful. Hence, the results pre-
sented in this study are descriptive in nature.
It may be of interest to summarize the results from
the present study in the context of safety data of these
agents from either clinical trials or EAPs. However,
there are differences between the population in the pre-
sent study and the populations in these other studies
that should be considered. For example, the present
study includes patients who are MKI-naïve, who may or
may not be cytokine naïve, while the clinical trial for
sunitinib included only patients who were cytokine-
naïve; the clinical trial for sorafenib included both cyto-
kine-naïve and cytokine-pretreated patients [1,2]. In this
way, the population in the present study may be more
comparable in composition to the EAP studies where
more than half of patients were cytokine-pretreated
[6,11]. However, there are differences that still remain
between this study and the EAPs studies. For example,
the present study had a considerably higher proportion
of cytokine pretreated patients in the sunitinib group
than did the sunitinib EAP (80% versus 68%) [6]. With
limited sample sizes, it is not possible to separate the
patients in the present study by cytokine pre-treatment
status. Furthermore, the proportion of patients with
Table 2 Adverse Events (≥ 5%) among Patients Receiving
First-Line Multikinase Inhibitor Treatment
Sunitinib Sorafenib
(N = 85) (N = 60)










Any adverse event 83 (97.6) 23 (27.1) 42 (70.0) 19 (31.7)
Fatigue/Asthenia 69 (81.2) 8 (9.4) 26 (43.3) 6 (10.0)
Mucositis/Stomatitis 50 (58.8) 2 (2.4) 16 (26.7) 0 (0.0)
Hand-foot syndrome 29 (34.1) 2 (2.4) 23 (38.3) 2 (3.3)
Diarrhea 26 (30.6) 0 (0.0) 19 (31.7) 2 (3.3)
Hypertension 35 (41.2) 3 (3.5) 6 (10.0) 3 (5.0)
Decreased taste
sensation
36 (42.4) 0 (0.0) 1 (1.7) 0 (0.0)
Abdominal pain 19 (22.4) 3 (3.5) 10 (16.7) 2 (3.3)
Nausea 25 (29.4) 3 (3.5) 2 (3.3) 0 (0.0)
Lack of appetite 12 (14.1) 0 (0.0) 5 (8.3) 1 (1.7)
Pain 13 (15.3) 0 (0.0) 4 (6.7) 1 (1.7)
Anorexia 15 (17.6) 5 (5.9) 1 (1.7) 0 (0.0)
Vomiting 15 (17.6) 5 (5.9) 1 (1.7) 0 (0.0)
Hemorrhage 12 (14.1) 0 (0.0) 1 (1.7) 0 (0.0)
Constipation 6 (7.1) 0 (0.0) 6 (10.0) 1 (1.7)
Edema 12 (14.1) 1 (1.2) 0 (0.0) 0 (0.0)
Dermatitis 6 (7.1) 0 (0.0) 4 (6.7) 1 (1.7)
Anemia 5 (5.9) 1 (1.2) 3 (5.0) 1 (1.7)
Erythema 7 (8.2) 1 (1.2) 1 (1.7) 0 (0.0)
Hypothyroidism 6 (7.1) 1 (1.2) 2 (3.3) 0 (0.0)
Skin rash 2 (2.4) 0 (0.0) 6 (10.0) 2 (3.3)
Dyspnea 4 (4.7) 0 (0.0) 3 (5.0) 2 (3.3)
Hemorrhoids 5 (5.9) 0 (0.0) 2 (3.3) 0 (0.0)
Alopecia 1 (1.2) 0 (0.0) 4 (6.7) 0 (0.0)
Note: Adverse events experienced by at least 5% of patients in at least one
treatment group are reported.
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specific types of metastatic sites varied between studies;
for example, in the current study, 16.5% of sunitinib
patients had brain metastasis whereas only 7% of
patients in the sunitinib EAP did [6].
One should consider that patients in the present study
were referred to the center mainly for enrollment into
clinical trials, and this is the priority. Since the vast
majority of the patients reported here were excluded
from clinical trials for several reasons (including comor-
bidities, not considered for the purposes of this paper),
they could be considered to be a poorer prognostic
group of RCC patients, definitely more close to patients
in everyday clinical practice.
For any grade adverse events, the present study found
fatigue/asthenia, followed by mucositis/stomatatis and
decreased taste sensation as the most frequent adverse
events associated with sunitinib while fatigue/asthenia,
hand-foot syndrome, and diarrhea were the most fre-
quent adverse events associated with sorafenib. This is
generally consistent with the findings for the EAPs for
each of these agents, where these adverse events were
among the most commonly reported adverse events.
The rates for some adverse events observed in the
present study were higher than may be expected com-
pared with findings from EAPs. For example, the
observed rates (any grade) for fatigue/asthenia of 81.2%
and for mucositis/stomatitis of 58.8% for sunitinib
appeared to be considerably higher than what may be
expected based on the sunitinib EAP (37% and 28%,
respectively). This finding may be due to various
underlying population differences noted above (specifi-
cally, a higher rate of cytokine refractory patients in
the present study). Additionally, in the present study
the rates (any grade) for fatigue/asthenia of 43.3% and
for hand-foot syndrome of 38.3% for sorafenib
appeared to be considerably higher than the corre-
sponding rates reported in the sorafenib EAP (grade 2+,
11% and 18.1%, respectively).
In addition, the length of time of patient follow-up
and frequency of patient visits may differ between set-
tings. Patients in clinical trials are observed for a finite
period of time while patients in a naturalistic setting
may have a longer observation period, which may result
in more adverse events being observed in clinical
Table 3 First-line Multikinase Inhibitor Treatment Patterns and Second-line Multikinase Inhibitor Treatment
Sunitinib Sorafenib
(N = 85) (N = 60)
Duration of treatment, months1
Median (95% CI) 6.6 (5.3, 11.1) 5.8 (4.1, 8.1)
Mean (SE) 9.9 (0.9) 8.3 (0.9)
Patients who discontinued first-line treatment, N (%) 66 (77.6) 51 (85.0)
Reasons for discontinuation, N (%)2
Adverse events 10 (11.8) 3 (5.0)
Progressive disease 53 (62.4) 35 (58.3)
Other 9 (10.6) 14 (23.3)
Patients with first-line treatment interruption, N (%) 29 (34.1) 16 (26.7)
Reasons for interruptions, N (%)3
Adverse Events 20 (23.5) 14 (23.3)
Other 15 (17.6) 3 (5.0)
Patients with first-line dose reduction, N (%) 30 (35.3) 23 (38.3)
Reasons for dose reduction, N (%)4
Adverse Events 26 (30.6) 22 (36.7)
General clinical conditions worsening 5 (5.9) 1 (1.7)
Patients who received second-line angiogenesis inhibitor, N (%) 15 (17.6) 23 (38.3)
Sunitinib, N (%) – 21 (35.0)
Sorafenib, N (%) 15 (17.6) –
Temsirolimus, N (%) 0 (0.0) 2 (3.3)
Notes:
1. 11 patients who received sunitinib and 6 patients who received sorafenib and who had not ended first-line treatment by the time of data collection were
treated as censored observations as of the date of last follow-up.
2. Patients may have more than one reason for discontinuation of first-line treatment.
3. For patients with more than one treatment interruption during the first-line treatment, the reasons for each treatment interruption are included.
4. For patients with more than one dose reduction during the first-line treatment, the reasons for each dose reduction are included.
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Table 4 Adverse Events Reported as Reasons for Treatment Modifications in First-line Multikinase Inhibitor Treatment
Sunitinib Sorafenib
(N = 85) (N = 60)
At least one treatment modification due to AEs, n (%) 34 (40.0) 27 (45.0)
Patients who discontinued first-line treatment due to AEs, n (%) 10 (11.8) 3 (5.0)
Adverse Eventsa
Anorexia 4 (4.7) 0 (0.0)
Fatigue/asthenia 3 (3.5) 1 (1.7)
Fever 2 (2.4) 0 (0.0)
Dyspnea 1 (1.2) 1 (1.7)
Abdominal pain 1 (1.2) 1 (1.7)
Skin rash 0 (0.0) 1 (1.7)
Patients with first-line treatment interruption due to AEs, n (%) 20 (23.5) 14 (23.3)
Adverse Eventsa,b
Fatigue/asthenia 8 (9.4) 2 (3.3)
Diarrhea 5 (5.9) 4 (6.7)
Hand-foot syndrome 2 (2.4) 3 (5.0)
Vomiting 5 (5.9) 0 (0.0)
Dyspnea 2 (2.4) 2 (3.3)
Anemia 2 (2.4) 1 (1.7)
Hypertension 2 (2.4) 1 (1.7)
Skin rash 0 (0.0) 3 (5.0)
Stomatitis/mucositis 3 (3.5) 0 (0.0)
Gastritis 2 (2.4) 0 (0.0)
Nausea 2 (2.4) 0 (0.0)
Edema 2 (2.4) 0 (0.0)
Ulcer 2 (2.4) 0 (0.0)
Patients with first-line dose reduction due to AEs, n (%) 26 (30.6) 22 (36.7)
Adverse Eventsa,b
Fatigue/asthenia 14 (16.5) 12 (20.0)
Hand-foot syndrome 3 (3.5) 11 (18.3)
Diarrhea 3 (3.5) 7 (11.7)
Stomatitis/mucositis 4 (4.7) 2 (3.3)
Vomiting 3 (3.5) 1 (1.7)
Dyspnea 1 (1.2) 2 (3.3)
Hypertension 1 (1.2) 2 (3.3)
Nausea 3 (3.5) 0 (0.0)
Pain 0 (0.0) 2 (3.3)
Stomach ache 1 (1.2) 2 (3.3)
Hiccup 2 (2.4) 0 (0.0)
Lack of appetite 0 (0.0) 2 (3.3)
Edema 2 (2.4) 0 (0.0)
Ulcer 2 (2.4) 0 (0.0)
AE = adverse event.
a. Patients may have reported more than 1 adverse event leading to a treatment modification.
b. Adverse events reported as reasons for at least 2% of patients in at least 1 treatment group are reported.
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settings. On the other hand, clinical trials have more
vigilant surveillance that could lead to higher observed
rates of adverse events compared to clinical settings,
where physicians may not record all adverse events or
proactively inquire patients about their adverse event
experiences.
Moreover, this study examined reasons for treatment
modifications. The rate of treatment discontinuation
was high in both groups, with most discontinuations
due to disease progression, and some discontinuations
due to adverse events. Adverse events were the most
frequently reported reasons for dose reductions and
treatment interruptions. These results suggested that
adverse events play an important role in decisions for
treatment modifications.
Although fatigue/asthenia, diarrhea, hand-foot syn-
drome, and vomiting appeared to be the most common
adverse events leading to treatment modifications, a
clear pattern associated with specific adverse events and
their impact on clinical decisions for treatment modifi-
cation remain to be further studied.
Due to the aforementioned differences between the
population of this study and that of the EAPs, and the
fact that this study focused on safety and treatment pat-
terns, the survival outcomes could not be formally com-
pared. Furthermore, it is difficult to compare these
outcomes across studies as clinical assessments to deter-
mine disease progression are conducted at different fre-
quencies in clinical trials and observational settings;
infrequent assessment for disease progression could lead
to overestimating PFS. In this study, the median PFS for
sunitinib was 7.3 months (95% CI 5.4-11.1), and the
median OS was 14.5 months (95%CI 12.5-20.0). In the
EAP, the median PFS for sunitinib was 10.9 months
(95% CI 10.3-11.2), and the median OS was 18.4 months
(95% CI 17.4-19.2). Median duration of sunitinib therapy
in this study was 6.6 months while median follow-up
duration in the EAP was 11.6 months. For patients
receiving sorafenib in this study, the median PFS was
7.3 months (95% CI 5.1-11.1), and the median OS was
15.0 months (95% CI 9.5-NR). In the EAP, the median
PFS was 5.5 months (95% CI 5.1-5.8), and the median
OS was 11.5 months (95%CI 10.6-12.0). Median
treatment duration for sorafenib in this study was
5.8 months while in the EAP it was 2.8 months. Based
on these qualitative observations, the survival outcomes
appear to be generally consistent with those from the
EAPs.
This study has several limitations. First, the study
sample was relatively small and came from a single ter-
tiary oncology center in Italy, limiting generalizability of
the study results. Future studies are needed to perform
similar evaluations in patients with mRCC in other
countries. Finally, because this is an observational study,
the lack of randomization and the potential resulting
selection bias limit the study’s ability to compare
between agents.
Conclusions
In this study, patients receiving sunitinib or sorafenib
frequently experienced treatment-related adverse events.
Progressive disease was the most common reason for
first-line MKI discontinuation, while adverse events
were the most common reasons for treatment interrup-
tions and dose reductions. While the rates of specific
adverse events were different in the current study com-
pared with the EAPs, the results from this retrospective
study in a real-world observational setting corroborate
findings from the EAPs that adverse events are com-
monly associated with sunitinib and sorafenib treatment.
Together, these results may suggest a need for addi-
tional effective and more tolerable treatments for
mRCC.
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